ABOS
Price
$1.79
Change
+$0.06 (+3.47%)
Updated
Jan 14 closing price
Capitalization
108.43M
74 days until earnings call
Intraday BUY SELL Signals
BEAM
Price
$35.41
Change
+$0.86 (+2.49%)
Updated
Jan 14 closing price
Capitalization
3.59B
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABOS vs BEAM

Header iconABOS vs BEAM Comparison
Open Charts ABOS vs BEAMBanner chart's image
Acumen Pharmaceuticals
Price$1.79
Change+$0.06 (+3.47%)
Volume$221.54K
Capitalization108.43M
Beam Therapeutics
Price$35.41
Change+$0.86 (+2.49%)
Volume$2.34M
Capitalization3.59B
ABOS vs BEAM Comparison Chart in %
View a ticker or compare two or three
VS
ABOS vs. BEAM commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and BEAM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (ABOS: $1.79 vs. BEAM: $35.41)
Brand notoriety: ABOS and BEAM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 121% vs. BEAM: 122%
Market capitalization -- ABOS: $108.43M vs. BEAM: $3.59B
ABOS [@Biotechnology] is valued at $108.43M. BEAM’s [@Biotechnology] market capitalization is $3.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 0 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • BEAM’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 4 TA indicator(s) are bullish while BEAM’s TA Score has 5 bullish TA indicator(s).

  • ABOS’s TA Score: 4 bullish, 5 bearish.
  • BEAM’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than ABOS.

Price Growth

ABOS (@Biotechnology) experienced а -10.05% price change this week, while BEAM (@Biotechnology) price change was +22.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

ABOS is expected to report earnings on Mar 30, 2026.

BEAM is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($3.59B) has a higher market cap than ABOS($108M). BEAM YTD gains are higher at: 27.742 vs. ABOS (-15.166). ABOS has higher annual earnings (EBITDA): -128.99M vs. BEAM (-434.55M). BEAM has more cash in the bank: 1.08B vs. ABOS (127M). ABOS has less debt than BEAM: ABOS (30.8M) vs BEAM (151M). BEAM has higher revenues than ABOS: BEAM (55.7M) vs ABOS (0).
ABOSBEAMABOS / BEAM
Capitalization108M3.59B3%
EBITDA-128.99M-434.55M30%
Gain YTD-15.16627.742-55%
P/E RatioN/AN/A-
Revenue055.7M-
Total Cash127M1.08B12%
Total Debt30.8M151M20%
FUNDAMENTALS RATINGS
BEAM: Fundamental Ratings
BEAM
OUTLOOK RATING
1..100
78
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABOSBEAM
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 24 days ago
79%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
ABOS
Daily Signal:
Gain/Loss:
BEAM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCVSX23.010.17
+0.74%
Victory Integrity Small-Cap Value C
TRSLX5.480.03
+0.55%
Transamerica Small Cap Value R
PMVYX18.77-0.12
-0.64%
Putnam Sustainable Future Y
AFYDX48.26-0.33
-0.68%
American Century Large Cap Equity Y
FDTRX201.87-3.67
-1.79%
Franklin DynaTech R6

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with CELC. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then CELC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
+3.47%
CELC - ABOS
44%
Loosely correlated
+9.86%
BEAM - ABOS
42%
Loosely correlated
+2.49%
SYRE - ABOS
40%
Loosely correlated
+5.17%
CRBU - ABOS
40%
Loosely correlated
+1.26%
MGX - ABOS
39%
Loosely correlated
+0.58%
More

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+2.49%
CRSP - BEAM
71%
Closely correlated
+1.26%
RXRX - BEAM
62%
Loosely correlated
+3.41%
NTLA - BEAM
61%
Loosely correlated
+2.39%
PRME - BEAM
59%
Loosely correlated
+3.61%
SYRE - BEAM
57%
Loosely correlated
+5.17%
More